lenalidomide has been researched along with ATLL in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, J; Fukuda, T; Inamoto, Y; Ito, A; Kim, SW; Takeda, W; Tanaka, T; Watanabe, M | 1 |
| Ando, K; Chiwata, M; Fujioka, M; Furumoto, T; Hata, T; Horai, M; Imaizumi, Y; Itonaga, H; Kasai, S; Kato, T; Miyazaki, Y; Moriuchi, Y; Nakashima, J; Sakamoto, H; Sato, S; Sawayama, Y; Taguchi, J; Toriyama, E; Yoshida, S | 1 |
| Challen, G; Harding, JC; Kim, Y; MacLeod, AR; Olson, SL; Ratner, L; Rauch, DA; Sundaramoorthi, H; Zhou, T | 1 |
| Arai, A; Nakayama, K; Tajika, K; Tamai, H | 1 |
| Iida, S; Inagaki, H; Ishida, T; Ito, A; Iwasaki, H; Kusumoto, S; Masaki, A; Murase, T; Muto, R; Nakano, N; Sakamoto, Y; Takeshita, M; Tashiro, Y; Tokunaga, M; Ueda, R; Utsunomiya, A; Yonekura, K | 1 |
| Aishima, S; Ando, T; Kidoguchi, K; Kimura, S; Kojima, K; Kubota, Y; Kusaba, K; Nakamura, H; Sano, H; Takase, Y; Yokoo, M; Yoshimura, M | 1 |
| Asada, H; Miyagawa, F; Miyao, M; Nishikawa, M; Ogawa, K; Yamamoto, S | 1 |
| Harewood, JCK; Phillips, AA | 1 |
| Aoyama, K; Arakawa, F; Morishige, S; Mouri, F; Nagafuji, K; Nakamura, T; Nishi, M; Ohshima, K; Osaki, K; Oya, S; Saruta, H; Seki, R; Yamaguchi, M; Yamasaki, Y | 1 |
| Moskowitz, AJ | 1 |
| Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A | 1 |
| Abe, Y; Fujiwara, H; Imaizumi, Y; Ishida, T; Ishizawa, K; Ito, S; Jo, T; Midorikawa, S; Moriuchi, Y; Nosaka, K; Ogura, M; Ohtsu, T; Otsuka, M; Ruiz, W; Taira, N; Tobinai, K; Tsukasaki, K; Yoshimitsu, M | 1 |
| Horwitz, SM; Mehta-Shah, N | 1 |
| Tobinai, K | 1 |
2 review(s) available for lenalidomide and ATLL
| Article | Year |
|---|---|
Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Human T-lymphotropic virus 1; Humans; Japan; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell | 2018 |
Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Japan; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Multicenter Studies as Topic; Purine Nucleosides; Pyrimidinones; Thalidomide; Treatment Outcome | 2010 |
2 trial(s) available for lenalidomide and ATLL
| Article | Year |
|---|---|
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell, Peripheral; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Young Adult | 2016 |
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Endpoint Determination; Female; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
10 other study(ies) available for lenalidomide and ATLL
| Article | Year |
|---|---|
Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Recurrence; Retrospective Studies | 2023 |
Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous | 2020 |
Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Gene Products, tax; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Interferon Regulatory Factors; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Mice; Oligonucleotides, Antisense; Signal Transduction; Thionucleotides | 2020 |
Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.
Topics: Antibodies, Monoclonal, Humanized; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma | 2021 |
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CD28 Antigens; Cyclophosphamide; DNA Copy Number Variations; Doxorubicin; Etoposide; Female; Genes, p53; Hematopoietic Stem Cell Transplantation; Humans; INDEL Mutation; Kaplan-Meier Estimate; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mutation; Nitrosourea Compounds; Polymorphism, Single Nucleotide; Prednisolone; Prednisone; Prognosis; Receptors, CCR4; Vincristine; Vindesine | 2021 |
Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide.
Topics: Cord Blood Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2018 |
Predisposition to multi-drug hypersensitivity after administration of mogamulizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Diuretics; Drug Eruptions; Esomeprazole; Factor Xa Inhibitors; Fatal Outcome; Female; Furosemide; Humans; Immunologic Factors; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Proton Pump Inhibitors; Pyridines; Thiazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.
Topics: Aged; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Pulse Therapy, Drug; Recurrence; Stevens-Johnson Syndrome; Transplantation, Haploidentical; Treatment Outcome | 2019 |
Lenalidomide in adult T-cell leukaemia-lymphoma.
Topics: Adult; Antineoplastic Agents; Humans; Lenalidomide; Leukemia; Leukemia-Lymphoma, Adult T-Cell; T-Lymphocytes; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide in Adult T-Cell Leukemia/Lymphoma.
Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Thalidomide; Treatment Outcome | 2016 |